Browsing Category
Pharma Industry News
4720 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
BridgeBio raises $1bn in preferred equity to fund rare disease product launches
BridgeBio’s $1 billion preferred equity raise strengthens BBIO’s balance sheet as Attruby grows and three rare disease launches approach.
BridgeBio Pharma weighs $1bn KKR, Sixth Street preferred equity deal as launch costs rise
BridgeBio Pharma may be preparing its balance sheet for three potential product launches, but the value of a $1 billion preferred equity deal will depend heavily on its undisclosed dividend, conversion and redemption terms.
Can potravitug justify Ipsen’s €700m-plus Memo Therapeutics acquisition?
Ipsen is acquiring Memo Therapeutics to secure potravitug, a clinical-stage antibody targeting a serious kidney transplant complication. The structure limits Ipsen’s upfront exposure while placing the larger valuation behind clinical, regulatory and commercial success.
Bajaj Healthcare (NSE: BAJAJHCARE) rallies 16% on Cenobamate approval milestone
BAJAJHCARE surged on India’s first Cenobamate recommendation. Final approval and launch economics must now justify the ₹1,183 crore valuation.
Ipsen to buy Kartos Therapeutics for up to $1.75bn as IPN nears 52-week high
Ipsen is buying Kartos for up to $1.75 billion. Read how navtemadlin could reshape its oncology pipeline, earnings outlook and IPN valuation after the deal.
Neuren Pharmaceuticals (ASX: NEU) jumped 45% in two sessions, but how much DAYBUE upside remains?
DAYBUE’s EU breakthrough sent NEU up 45% in two sessions. The harder test is whether royalties and NNZ-2591 justify A$2.25 billion.
Nuvectis Pharma just raised $100 million, so why are NVCT shareholders selling?
Nuvectis Pharma shares fell 19% after a $100 million offering priced at $20. Read what dilution, runway and pipeline expansion mean for NVCT investors now!
Why Avacta’s (AVCT) smallest FAP signal could create a much bigger opportunity for pre|CISION
Avacta Group’s latest faridoxorubicin findings suggest pre|CISION may activate effectively even in tumours with minimal FAP expression, potentially widening the platform’s commercial reach while raising the importance of mature progression-free survival data and a development partnership.
Scancell confirms Neuphoria reverse-merger talks as SCLP targets Nasdaq and Phase 3 funding
Scancell is discussing an all-share acquisition of Neuphoria Therapeutics that could secure a Nasdaq listing and strengthen funding options for the global Phase 3 trial of iSCIB1+.
Moderna (MRNA) surges to 52-week high as flu vaccine win and Science Day pipeline reset reframe the post-COVID story
Moderna (NASDAQ: MRNA) surges 12 percent to 52-week high above $69 on Science Day pipeline reset, FDA flu panel win and BioNTech plant acquisition plans.